MDB Capital Q3 Loss Widens to $16.4M on $9.86M eXoZymes Impairment
MDBH sits 69% above its 52-week low of $0.89.
Summary
MDB Capital's Q3 loss widened to $16.4M, driven by a $9.86M non-cash impairment of its eXoZymes stake, while cash fell to $8.3M after $6.7M of nine-month operating burn.
Key Events · Earnings and Guidance · MDBH
-
Q3 Loss Widens on Impairment
Net loss attributable to MDB was $16.4M for the three months ended September 30, 2026, versus $4.7M a year earlier, including a $9.86M impairment of the eXoZymes equity method investment.
-
Nine-Month Loss Nearly Doubles
Net loss for the nine months reached $32.5M versus $19.5M in 2025, with $13.2M of equity in loss of the eXoZymes investee and $5.9M of unrealized losses on broker-dealer securities.
-
Cash Falls to $8.3M
Cash and equivalents were $8.3M at September 30, 2026, down from $13.2M at December 31, 2025, after $6.7M of operating cash burn; working capital fell $5.7M to $9.9M.
-
Fee Income Up 54%
Nine-month fee income rose to $3.3M from $2.1M, plus $892K of related-party fee income from eXoZymes, though Q3 fee income was only $333K.
Analysis · MDBH · Finance
The quarter's loss more than tripled year over year, and almost all of the damage is a non-cash write-down: MDB marked its eXoZymes stake down by $9.86M after the shares kept trading below cost. Strip that out and the operating business is still losing money, but the broker-dealer is generating more fees — nine-month fee income rose 54% to $3.3M. The real constraint is cash: $8.3M on hand against $6.7M burned in nine months leaves a thin runway, and the company has no debt drawn on its $2.0M revolver to fall back on.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDBH was trading at $1.50 on NASDAQ in the Finance sector, with a market capitalization of approximately $15.7M. The 52-week trading range was $0.89 to $4.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.